Homozygous Familial Hypercholesterolemia (HoFH) Pipeline Review, H1 2018 - Therapeutics Development & Assessment, Key Companies Involved, Drug Profiles - ResearchAndMarkets.com

DUBLIN--()--The "Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 5, 1, 2 and 1 respectively.

Companies Mentioned

  • Akcea Therapeutics Inc
  • CymaBay Therapeutics Inc
  • Daewoong Co Ltd
  • Gemphire Therapeutics Inc
  • LipimetiX Development Inc
  • Madrigal Pharmaceuticals Inc
  • Regeneron Pharmaceuticals Inc
  • RegenxBio Inc
  • The Medicines Company

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Homozygous Familial Hypercholesterolemia (HoFH) - Overview
  4. Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Homozygous Familial Hypercholesterolemia (HoFH) - Companies Involved in Therapeutics Development
  14. Homozygous Familial Hypercholesterolemia (HoFH) - Drug Profiles
  15. Homozygous Familial Hypercholesterolemia (HoFH) - Dormant Projects
  16. Homozygous Familial Hypercholesterolemia (HoFH) - Discontinued Products
  17. Homozygous Familial Hypercholesterolemia (HoFH) - Product Development Milestones
  18. Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/t2hlrv/homozygous?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs